Wednesday, 12 October 2011 09:00 AM
OTTAWA, ONT., October 11, 2011 - A strong turnout at two veterinarian stem cell knowledge sessions held recently in Montreal, Que. and Ottawa, Ont. has resulted in over 50 more small animal and horse veterinarians in Canada trained and accredited to perform VetStem RC Regenerative Cell Therapy on patients.
"The wet labs and credentialing courses provide veterinarians with the knowledge necessary to perform VetStem RC Regenerative Cell Therapy treatments on companion animals," says Charlotte Foster, Avivagen Animal Health sales and marketing director. "After speaking with many veterinarians in attendance at the course, they were thinking of clients who would benefit from the therapy."
Dr. Charles Bruce, small animal surgeon at the Alta Vista Animal Hospital in Ottawa has been using VetStem RC Regenerative Cells at the clinic.
"We have been using the VetStem RC Regenerative Cells therapy to treat arthritic joints in dogs that have become intolerant to medications or don't tolerate traditional medications and as part of a multi-modal approach," he says. "It has also been extremely successful in dogs with tendon ruptures. The therapy has provided increased mobility, activity levels and comfort for my patients, and medication levels have gone down."
Dr. Bruce says he believes the therapy will become more popular in the future for arthritic animals and to treat systemic auto-immune diseases in dogs and cats.
Dr. Anthony Kahn, veterinarian at Centre Vétérinaire Laval in Laval, Que. attended the Montreal VetStem RC credentialing course and found it beneficial.
"The course was very informative and gave me a better sense of what cases would be appropriate for this therapy as well as the advantages of stem cells derived from adipose tissue," he notes. "We see patients with advanced degenerative orthopedic diseases such as osteoarthritis in our practice. I have been recommending the therapy for these types of cases."
VetStem RC Regenerative Cell Therapy is scientifically proven for treatment of arthritic conditions, and joint and ligament injuries in dogs, cats and horses. The therapy uses regenerative cells derived from an animal's own fat tissue. A small amount of fat tissue is extracted by the patient's veterinarian and then couriered to Avivagen Animal Health's new, state-of-the-art, Canadian laboratory facility in Prince Edward Island. The cells are processed and counted, following stringent sterility and quality assurance guidelines. The number of cells required for the immediate treatment are then returned to the veterinarian for injection into the patient, often within 48 hours of extraction. Extra cells are stored by Avivagen Animal Health for future treatments if the animal has a later need of treatment.
Avivagen is a new Canadian company dedicated to improving the quality of life of animals through science-based, natural health products proven in clinical trials. Avivagen is a subsidiary of Chemaphor Inc., a Canadian company dedicated to the research and development of science-based, natural products for people and animals. VetStem RC Regenerative Cell Therapy has been exclusively licensed by Avivagen for the Canadian animal health market from Vet-Stem (USA).
Chemaphor is listed on the TSX Venture Exchange and trades under the symbol CFR.
###
For more information:
David HankinsonGraham Burton, PhD CEO, Avivagen Animal Health Inc.President and Co-Founder, Chemaphor Inc. Phone: 902-825-9270Phone: 613-990-0969 [email protected]@chemaphor.com
Investor Relations:Media Group:
Evolution Group Inc.McCormick Global Communications Sylvain ArchambaultKaren Sample 514-448-4887 / Toll free: 866-703-4887Phone: 519-475-6378 [email protected]@mccormickglobal.com www.evolutiongrp.com
TM Trademark of Chemaphor Inc. VetStem RC Regenerative Cell Therapy is licensed from Vet-Stem, Inc.
Forward Looking Statements This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Chemaphor Inc. and Avivagen Animal Health Inc. and the environment in which their respective businesses operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Chemaphor Inc. and Avivagen Animal Health Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Chemaphor assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. The results of treatment described above are based on historical results. Different animals may experience different results from the treatments described above. Anyone interested in the treatments described above should discuss the potential benefits and risks of such treatments with their veterinarian. The interest expressed by session attendees may not translate into orders for products.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.